Cereno Scientific AB
- Biotech or pharma, therapeutic R&D
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Cereno's pipeline includes an HDACi portfolio with two drug candidates in clinical phase – CS1 in PAH and CS014 in IPF. CS1 completed Phase 2a tial and, our novel HDACi CS014 is progressing towards completion of Phase I with topline results expected mid-2025.
In the preclinical stage, the pipeline comprises the drug candidate CS585, a novel prostacyclin (IP) receptor agonist, that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease.
Near term upcoming milestone:
CS1 Expanded Access Program Interim Data Readout - June 2025
CS014 Phase 1 Topline results - June 2025
CS1 Phase 2b program approval - Q3 2023
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}